Protein Biomarkers and Host RNA Expression Profiles in Congenital Cytomegalovirus Infection
Key facts
- Where
- Copenhagen, DenmarkSee the 2 sites
Where in Denmark
- Department of Congenital Disorders, Statens Serum InstitutCopenhagen, DenmarkContact: David M Hougaard, D.Sc (med)Taking people
- Department of Paediatrics and Adolescent Medicine, RigshospitaletCopenhagen, DenmarkContact: Kia Hee Schultz Dungu, MDTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Copenhagen University Hospital, Rigshospitalet
- Trial code
- NCT07635368
- Record updated
- 9 June 2026
- Original description
This study seeks to identify and test host protein biomarkers and RNA expression profiles in dried blood spot samples as novel diagnostic markers of congenital cytomegalovirus sequelae and to improve the understanding of the pathogenesis of the disease.Read full original descriptionShow less
This study seeks to identify and test host protein biomarkers and RNA expression profiles in dried blood spot samples as novel diagnostic markers of congenital cytomegalovirus sequelae and to improve the understanding of the pathogenesis of the disease.
Inclusion: Children born between 1 January 2010 and 31 December 2025 with an available neonatal dried blood spot sample collected through the Danish National Newborn Screening Program; Cases: children with verified congenital CMV infection, defined as a positive CMV PCR result on neonatal dried blood spot, blood, or urine collected within the neonatal period; Controls: children without evidence of congenital CMV infection selected from the same newborn screening population and matched to cases on sex, gestational age, birthweight, and age at DBS sampling.
Exclusion: DBS samples not approved for research use; DBS samples with insufficient blood material for RNA expression profiling and/or proteomic analyses; Samples with inadequate analytical quality for molecular or proteomic analyses.